Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano T, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: hara s. Prostate. 2023 May;83(6):563-571. doi: 10.1002/pros.24488. Epub 2023 Jan 20. Prostate. 2023. PMID: 36661102
Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
Hara S, Mori K, Fukuokaya W, Tomomasa N, Oguchi T, Takahashi Y, Saito S, Katami J, Sano T, Kadena S, Hashimoto M, Yata Y, Nishi E, Suhara Y, Takamizawa S, Kurawaki S, Suzuki H, Miyajima K, Iwatani K, Urabe F, Ito K, Yanagisawa T, Tsuzuki S, Shimomura T, Kimura T. Hara S, et al. Int J Clin Oncol. 2024 Aug;29(8):1191-1197. doi: 10.1007/s10147-024-02548-6. Epub 2024 May 20. Int J Clin Oncol. 2024. PMID: 38769191
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study.
Hara S, Urabe F, Tashiro K, Goto Y, Iwamoto Y, Ohtsuka T, Fukuokaya W, Imai Y, Iwatani K, Atsuta M, Mori K, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Murakami M, Tsuzuki S, Yanada BA, Hata K, Furuta A, Yamada H, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Hara S, et al. Jpn J Clin Oncol. 2024 Oct 19:hyae146. doi: 10.1093/jjco/hyae146. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39426804
Predicting pathological upstaging after radical nephroureterectomy in patients with upper tract urothelial carcinoma: results from a multicenter cohort study.
Yamaguchi R, Kagawa H, Yoshihara K, Yamamoto S, Hara S, Miyajima K, Enei Y, Fukuokaya W, Iwatani K, Imai Y, Atsuta M, Mori K, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Ishii G, Higuchi T, Sato S, Yamada Y, Furuta A, Shimomura T, Kimura T, Miki J, Urabe F. Yamaguchi R, et al. Among authors: hara s. Transl Androl Urol. 2024 Nov 30;13(11):2384-2395. doi: 10.21037/tau-24-357. Epub 2024 Nov 27. Transl Androl Urol. 2024. PMID: 39698572 Free PMC article.
2,225 results